These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 17698862

  • 21. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
    Ricart E, Bouma G, Peña AS.
    Drugs Today (Barc); 2002 Nov; 38(11):725-44. PubMed ID: 12582457
    [Abstract] [Full Text] [Related]

  • 22. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C.
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [Abstract] [Full Text] [Related]

  • 23. Immunosuppressive therapies for inflammatory bowel disease.
    Zenlea T, Peppercorn MA.
    World J Gastroenterol; 2014 Mar 28; 20(12):3146-52. PubMed ID: 24696600
    [Abstract] [Full Text] [Related]

  • 24. The use of biologic agents in pediatric inflammatory bowel disease.
    Yang LS, Alex G, Catto-Smith AG.
    Curr Opin Pediatr; 2012 Oct 28; 24(5):609-14. PubMed ID: 22828183
    [Abstract] [Full Text] [Related]

  • 25. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J.
    Gut; 2009 Apr 28; 58(4):477-8. PubMed ID: 19299379
    [No Abstract] [Full Text] [Related]

  • 26. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Incà R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M, Italian Society of Gastroenterology, Italian Group for the study of Inflammatory Bowel Disease.
    Dig Liver Dis; 2011 Jan 28; 43(1):1-20. PubMed ID: 20843756
    [Abstract] [Full Text] [Related]

  • 27. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.
    Ha C, Mathur J, Kornbluth A.
    Expert Rev Gastroenterol Hepatol; 2015 Apr 28; 9(4):497-505. PubMed ID: 25600263
    [Abstract] [Full Text] [Related]

  • 28. Infliximab in ulcerative colitis.
    Aberra FN, Lichtenstein GR.
    Gastroenterol Clin North Am; 2006 Dec 28; 35(4):821-36. PubMed ID: 17129815
    [Abstract] [Full Text] [Related]

  • 29. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2006 Dec 28; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

  • 30. [Treatment of chronic inflammatory bowel diseases].
    Lémann M.
    Bull Acad Natl Med; 2007 Jun 28; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [Abstract] [Full Text] [Related]

  • 31. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G.
    Gastroenterol Clin Biol; 2009 Jun 28; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [Abstract] [Full Text] [Related]

  • 32. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
    Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH.
    Aliment Pharmacol Ther; 2012 Sep 28; 36(6):569-74. PubMed ID: 22779779
    [Abstract] [Full Text] [Related]

  • 33. Medical treatment of inflammatory bowel diseases.
    Van Assche G, Vermeire S, Rutgeerts P.
    Curr Opin Gastroenterol; 2005 Jul 28; 21(4):443-7. PubMed ID: 15930985
    [Abstract] [Full Text] [Related]

  • 34. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J, Niemelä S.
    Duodecim; 1999 Jul 28; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract] [Full Text] [Related]

  • 35. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ, Cominelli F.
    Adv Intern Med; 1998 Jul 28; 43():143-74. PubMed ID: 9506181
    [No Abstract] [Full Text] [Related]

  • 36. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G, Vermeire S, Rutgeerts P.
    Eur J Pharmacol; 2009 Nov 25; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [Abstract] [Full Text] [Related]

  • 37. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2005 Nov 25; 5(1):10-8. PubMed ID: 15741928
    [Abstract] [Full Text] [Related]

  • 38. [Epidemiology, predictors and clinical aspects of loss of response to biological therapy].
    Lorinczy K, Miheller P, Kiss SL, Lakatos PL.
    Orv Hetil; 2012 Feb 05; 153(5):163-73. PubMed ID: 22275731
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC.
    Int Rev Immunol; 2010 Feb 05; 29(1):4-37. PubMed ID: 20100080
    [Abstract] [Full Text] [Related]

  • 40. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY, Sanderson JD, Irving PM.
    Eur J Gastroenterol Hepatol; 2012 Sep 05; 24(9):1078-85. PubMed ID: 22647738
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.